This Best Practice in Patient Recruitment report displays what percentages of patients are recruited from and where.
The stakes are high when it comes to clinical trials. Each day a trial goes beyond its intended deadline delays treatment for patients who would benefit from the medication and puts the sponsor organization at risk for lost revenue. Industry Standard Research’s Best Practices in Patient Recruitment report, based off of primary research with sponsors, CROs, and sites, includes an in-depth analysis of the industry’s strategies for completing a trial on-time and within budget.
One of the key findings in the report relates back to the use of specialized patient recruitment firms. According to both sponsors and CROs, engaging a specialized patient recruitment firm is a better value than adding more sites to the study. This is, in part, due to specialized recruitment firms having their own database of patients-one of the most important resources when recruiting for a clinical trial. As detailed in the chart below, the bulk of patients currently come from Existing patients at sites / in-house patient databases. While this is predicted to remain true for the next two years, respondents anticipate a smaller proportion of patients will come from in-house site databases by 2018.
“Currently, what percentage of your patients are recruited directly via the following sources? Your responses should add to 100%.”
ISR has collected additional insights to improve the efficacy of recruitment efforts in its Best Practices in Patient Recruitment report, including:
The Best Practices in Patient Recruitment is a valuable tool for anyone charged with patient recruitment. It will assist readers in knowing when and how to engage a specialized patient recruitment firm to get the best value and how to implement the best practices identified by industry peers to improve the likelihood of your trial finishing on-time and within budget. For more information about the report, please visit ISR’s report page at http://www.isrreports.com/reports/best-practices-patient-recruitment/
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Phase III Trials Confirm Remibrutinib Effectively Reduces Chronic Spontaneous Urticaria Symptoms
March 6th 2025Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic spontaneous urticaria symptoms in patients unresponsive to second-generation H1-antihistamines.